hotspot -WSS

hotspot

author：comprehensive 2025-10-01 09:00:24 - browse：429

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

WSS

Stem cell clinics for heart failure: buyer be wary

New guidelines on severe brain injury complicate already difficult decisions

Stem cell clinics for heart failure: buyer be wary

CDC concerned about possible undetected monkeypox spread in U.K.

Dramatically reducing cancer deaths requires the PASTEUR Act

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

knowledge

hotspot

hotspot

Peter Hotez and the public health issue of online harassment

The science behind Janet Jackson's pregnancy at 49

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The story of mRNA: From a loose idea to a tool that may help curb Covid

Jerome Adams on the need for new antivirals for Covid

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

In age of alternative facts, a scholarly course on calling out crap

Microsoft strikes partnership with Duke Health to advance health AI

Anesthesiologist group: stop taking Ozempic before surgery

What the cancer research community can learn from the Covid response

entertainment

Verily hires former Apple Health leader as chief scientific officer

Stem cell clinics for heart failure: buyer be wary

CDC concerned about possible undetected monkeypox spread in U.K.

Dramatically reducing cancer deaths requires the PASTEUR Act

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Stem cell clinics for heart failure: buyer be wary

knowledge

entertainment

focus

entertainment